Google’s venture into the biological frontier is entering a high-stakes phase as Isomorphic Labs, the drug-discovery spin-off from AI powerhouse DeepMind, prepares for a massive capital injection. Sources familiar with the matter indicate the firm is in advanced discussions to raise upwards of $2 billion, a figure that would underscore the immense market confidence in AI’s potential to overhaul traditional pharmaceutical R&D.
Thrive Capital, which led the startup’s initial funding round last year, is expected to spearhead this latest effort. The round also sees continued participation from parent company Alphabet, highlighting the tech giant’s commitment to maintaining a dominant footprint in the intersection of artificial intelligence and life sciences.
Isomorphic Labs was established to commercialize the breakthroughs of AlphaFold, DeepMind’s Nobel-caliber system that solved the 50-year-old challenge of predicting protein structures. By treating the process of drug discovery as an information-processing problem, the company aims to drastically reduce the decade-long timelines and multi-billion-dollar costs traditionally associated with bringing new medicines to market.
This funding surge arrives as the 'Generative AI for Biology' sector becomes a primary focus for global venture capital. While the broader tech market has faced selective headwinds, the promise of proprietary AI models identifying novel compounds for hard-to-treat diseases remains a high-conviction bet for institutional investors seeking the next trillion-dollar industry shift.